Blueprint Medicines Corporation Stock News

Blueprint Medicines delivered an exceptional quarter with a positive reception for Ayvakit in its first full-quarter post-launch. More than 800 patients were using the ISM treatment at the end of Q3.

Blueprint Medicines (BPMC) came out with a quarterly loss of $2.20 per share versus the Zacks Consensus Estimate of a loss of $2.39. This compares to loss of $2.23 per share a year ago.

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

On August 2, Blueprint Medicines, a pharmaceutical company developing medicines for treating cancer and blood diseases, released its financial results for the second quarter of 2023. Blueprint Medicin

Blueprint (BPMC) reports better-than-expected second-quarter 2023 results, driven by increased Ayvakit sales, following FDA approval in a new indication.

Blueprint Medicines announced increased revenue and decreased losses. The company's lead therapy, Ayvakit, is now approved for three indications.

Although the revenue and EPS for Blueprint Medicines (BPMC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with W

CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

Major large cap pharmaceutical firms often dominate the headlines. However, small cap drug companies also contribute significantly to scientific advancements.

Blueprint Medicines just got a critical green light from regulators for Ayvakit. This treats a rare and often debilitating blood disorder affecting 1 in 10,000 people.

Blueprint Medicines focuses on developing precision therapies for genomically defined cancers and blood disorders, with two approved drugs and multiple ongoing programs. The company's stock has risen

Blueprint Medicines (BPMC) announces better-than-expected results for first-quarter 2023 as it beats estimates for both earnings and revenues. Stock surges 13% following the news.

Blueprint Medicines (BPMC) announces better-than-expected financial performance in fourth-quarter and full-year 2022. Stock up in the aftermarket hours, following the news release.

Blueprint Medicines Corporation (NASDAQ:BPMC ) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Havi

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.93% and 18.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?